Press Releases October 2, 2026 09:00 AM

iTonic Holdings Ltd Announces 16-for-1 Share Consolidation Effective October 6, 2026

iTonic Holdings approves 16-for-1 share consolidation to support Nasdaq compliance with minimum bid price rule

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
ITOC

iTonic Holdings Ltd, a China-based healthcare technology company listed on Nasdaq, announced a 16-for-1 share consolidation effective October 6, 2026, along with an increase in authorized share capital. This move aims to increase the trading price per share to meet Nasdaq's minimum $1.00 bid price requirement by the October 19, 2026 deadline. Despite the consolidation, there is no assurance the company will regain compliance with Nasdaq listing standards.

iTonic Holdings Ltd Announces 16-for-1 Share Consolidation Effective October 6, 2026
ITOC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The company will consolidate every 16 class A and class B ordinary shares into 1 share, reducing shares outstanding from approximately 109 million to 6.8 million for class A shares.
  • The authorized share capital will increase significantly from US$50,000 to US$800,000, allowing issuance of more shares in future capital raises.
  • The share consolidation intends to boost the stock price above Nasdaq’s minimum $1.00 bid price to avoid potential delisting, with a compliance deadline of October 19, 2026.

BEIJING, China, Oct. 02, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (Nasdaq: ITOC) (the “Company”), a healthcare company developing digital medical technologies, today announced that at the extraordinary general meeting (the “EGM”) held on September 9, 2026, shareholders approved, among other matters, a 16-for-1 consolidation of the Company’s class A ordinary shares (the “Class A Ordinary Shares”) and class B ordinary shares (the “Class B Ordinary Shares”) (the “Share Consolidation”) and a related increase in authorized share capital. The Share Consolidation will combine every sixteen (16) issued and unissued Class A Ordinary Shares, par value US$0.0001 each, into one (1) Class A Ordinary Share, par value US$0.0016, and every sixteen (16) issued and unissued Class B Ordinary Shares, par value US$0.0001 each, into one (1) Class B Ordinary Share, par value US$0.0016.

The Share Consolidation will take effect at 12:01 a.m. Eastern Time on October 6, 2026 (the “Effective Date”), subject to completion of applicable corporate requirements and The Nasdaq Stock Market LLC (“Nasdaq”) not objecting. Upon the opening of the market on October 6, 2026, the Company’s Class A Ordinary Shares are expected to begin trading on The Nasdaq Capital Market on a post-Share Consolidation basis under the current symbol “ITOC”. The new CUSIP number for the Class A Ordinary Shares following the Share Consolidation will be G71399110, replacing the current CUSIP number G71399102.

The Share Consolidation will reduce the issued and outstanding Class A Ordinary Shares from 109,382,000 to approximately 6,836,375 and the issued and outstanding Class B Ordinary Shares from 7,668,000 to approximately 479,250. No fractional shares will be issued in connection with the Share Consolidation. Any fractional entitlement resulting from the Share Consolidation will be rounded up to the next whole Class A Ordinary Share or Class B Ordinary Share, as applicable.

Immediately following the Share Consolidation, the Company’s authorized share capital will remain US$50,000, divided into 25,000,000 Class A Ordinary Shares and 6,250,000 Class B Ordinary Shares, each of par value US$0.0016. The related share capital increase approved at the EGM will then increase the authorized share capital to US$800,000, divided into 400,000,000 Class A Ordinary Shares and 100,000,000 Class B Ordinary Shares, each of par value US$0.0016 (the “Share Capital Increase”). The Share Capital Increase creates additional authorized but unissued shares and does not itself increase the number of shares outstanding. The fourth amended and restated memorandum and articles of association approved at the EGM will take effect upon the Share Consolidation and the Share Capital Increase becoming effective.

Proportionate adjustments will be made, as applicable, to the number of shares issuable and the exercise or conversion prices under any outstanding options, warrants and convertible or exchangeable securities, and to share reserves under the Company’s equity incentive plans, in accordance with their respective terms.

The Share Consolidation is intended to increase the trading price per Class A Ordinary Share to support the Company’s efforts to regain compliance with the US$1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As previously disclosed, Nasdaq granted the Company until October 19, 2026 to regain compliance. There can be no assurance that the Share Consolidation will enable the Company to regain or maintain compliance with Nasdaq’s listing requirements.

About iTonic Holdings Ltd

iTonic Holdings Ltd (Nasdaq: ITOC) is a technology-driven healthcare company focused on developing innovative digital medical solutions. Through strategic investments and technology partnerships, the Company seeks to advance healthcare transformation through artificial intelligence, automation and intelligent data platforms. For more information, please visit: http://www.ftzy.com.cn/ir/overview.php

Forward-Looking Statements

This press release contains forward-looking statements under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These include statements about the anticipated timing and implementation of the Share Consolidation, the Share Capital Increase and the amended and restated memorandum and articles of association; the number of shares outstanding after the Share Consolidation; post-consolidation trading and share prices; and the Company’s ability to regain or maintain compliance with Nasdaq’s listing requirements. Such statements reflect current expectations and assumptions and are subject to risks and uncertainties. Actual outcomes could differ materially because of delays in completing corporate or market implementation requirements, changes in the number of outstanding shares, market conditions, trading volatility, the Company’s financial and operating performance, and the risks described in the Company’s most recent annual report on Form 20-F and other SEC filings. Forward-looking statements speak only as of the date made. The Company undertakes no obligation to update them, except as required by law.

Investor Relations Contact

iTonic Holdings Ltd

Investor Relations

Email: [email protected]

LLYC

Jackson Lin

Phone: +1-646-717-4593

Email: [email protected]


Risks

  • There is no guarantee the consolidation will achieve Nasdaq compliance if the share price does not improve sufficiently, risking delisting from Nasdaq.
  • Market volatility and overall company performance could affect the stock price post-consolidation, impacting investor confidence and liquidity.
  • Forward-looking statements highlight uncertainties including delays in corporate actions, changes in outstanding shares, and risks outlined in the company’s SEC filings, posing potential impacts to stock valuation and listing status.

More from Press Releases

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 Oct 2, 2026 Meet FORTITUDE™: The Single Chip Supercharging Data Speed and System Performance Oct 2, 2026 SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026 Oct 2, 2026 Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug Oct 2, 2026 newcleo plc Reports First Half 2026 Financial and Operational Results Oct 2, 2026